Trace Launches With $101m To Pursue ALS Drug Based On Genomic Insights

Could Address Up To 97% Of Patients

 
• By Mandy Jackson
  
Trace's lead drug candidate targets UNC13A mRNA splicing to treat ALS (Shutterstock)

More from Financing

More from Scrip